Gene Editing's 2026 Reality Check: Billion-Dollar Bets and the AI HorizonGlobal Report·2 days ago, 04:17 AMVRTX+1.50%CRSP-2.88%
Cathie Wood is buying this up-and-coming biotech stock. Should you follow her lead?MSN·Jul 20 at 01:43 PMBEAM-2.89%
M&A, AI Drug Discovery, and Late-Stage Clinical Readouts Define US Biotech Q2 TrajectoryGlobal Report·Jul 18 at 04:13 AMAMGN+1.53%CRSP-2.88%
ARK Invest snaps up $16.7M in SPCX shares, trims Deere exposureMSN·Jul 16 at 03:57 AMTWST-1.58%TXG-2.95%
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal BattleUnusual Whales·Jul 8 at 01:27 PMBEAM-2.89%PRME-1.18%
Prime Medicine wins arbitration with Beam over AATD therapy PM647PUBT·Jul 8 at 07:04 AMPRME-1.18%BEAM-2.89%
Russell Value Index Additions Could Be A Game Changer For Beam Therapeutics (BEAM)Simplywall·Jul 7 at 03:01 AMBEAM-2.89%
Beam Therapeutics Inc. Stock 12‑Month Price Target Cut to $49.87, Implies 43% UpsideTradingView·Jul 3 at 11:20 PMBEAM-2.89%
Beam Therapeutics CEO John M. Evans disposes of 49,000 common shares worth $1.72 millionPUBT·Jul 1 at 03:05 PMBEAM-2.89%
Beam Therapeutics (NASDAQ:BEAM) Insider Sells $1,172,024.64 in StockMarket Beat·Jun 29 at 02:07 PMBEAM-2.89%
Beam Therapeutics (NASDAQ:BEAM) Reaches New 1-Year High - Still a Buy?Market Beat·Jun 22 at 10:20 AMBEAM-2.89%
